NewEdge Advisors’s Zevra Therapeutics ZVRA Stock Holding History

NewEdge Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,000	Closed	-$37.3K	–	4407
2026 Q1	$37.3K	Hold	4,000	–	–	﹤0.01%	3018
2025 Q4	$35.8K	Sell	4,000 -18,338	-82%	-$173K	﹤0.01%	3058
2025 Q3	$212K	Buy	22,338 +18,338	+458%	+$184K	﹤0.01%	2381
2025 Q2	$35.2K	Hold	4,000	–	–	﹤0.01%	2767
2025 Q1	$30K	Hold	4,000	–	–	﹤0.01%	2724
2024 Q4	$33.4K	Hold	4,000	–	–	﹤0.01%	2658
2024 Q3	$27.8K	Hold	4,000	–	–	﹤0.01%	2621
2024 Q2	$19.6K	Sell	4,000 -24	-0.6%	-$114	﹤0.01%	2634
2024 Q1	$23.3K	Sell	4,024 -450	-10%	-$2.77K	﹤0.01%	2582
2023 Q4	$29.3K	Sell	4,474 -426	-9%	-$1.99K	﹤0.01%	2423
2023 Q3	$23.6K	Hold	4,900	–	–	﹤0.01%	2340
2023 Q2	$25K	Sell	4,900 -300	-6%	-$1.62K	﹤0.01%	2313
2023 Q1	$28.6K	Sell	5,200 -1,000	-16%	-$5.29K	﹤0.01%	2218
2022 Q4	$4.61K	Buy	+6,200	New	+$31.5K	﹤0.01%	2623

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NewEdge Advisors's ZVRA Position: Q2 2026 in Review

NewEdge Advisors sold out of Zevra Therapeutics (ZVRA) in Q2 2026, closing a stake of 4,000 shares — an estimated $37.3K sold.

NewEdge Advisors first reported a position in ZVRA in Q4 2022 and held it in 14 quarters. The position peaked at $212K in Q3 2025. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

NewEdge Advisors reported no remaining Zevra Therapeutics position as of Q2 2026 after selling out during the quarter.
NewEdge Advisors sold 4,000 Zevra Therapeutics shares in Q2 2026, an estimated $37.3K.
NewEdge Advisors first reported a position in Zevra Therapeutics in Q4 2022 and held it in 14 quarters.
NewEdge Advisors's Zevra Therapeutics position peaked at $212K in Q3 2025.
158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.